Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy. 1974

J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010648 Phenylacetates Derivatives of phenylacetic acid. Included under this heading are a variety of acid forms, salts, esters, and amides that contain the benzeneacetic acid structure. Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ACETIC ACID. Benzeneacetates,Benzeneacetic Acids,Phenylacetic Acids,Acids, Benzeneacetic,Acids, Phenylacetic
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D004296 Dopa Decarboxylase One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of DOPA to DOPAMINE. It is of clinical importance in the treatment of Parkinson's disease. Decarboxylase, Dopa
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females

Related Publications

J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
March 1978, No shinkei geka. Neurological surgery,
J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
June 2010, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
January 1973, Diseases of the nervous system,
J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
May 1973, Journal of the neurological sciences,
J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
September 1971, Clinical chemistry,
J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
January 1971, Soins; la revue de reference infirmiere,
J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
June 1970, The Journal of the Florida Medical Association,
J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
June 1972, The Nova Scotia medical bulletin,
J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
May 1971, Virginia medical monthly,
J Korf, and H M van Praag, and D Schut, and R J Nienhuis, and J P Lakke
January 2019, Frontiers in pharmacology,
Copied contents to your clipboard!